Navamedic ASA Net Assets
Navamedic ASA net assets. Based on the latest financial reports, Navamedic ASA (NAVA) has net assets worth Nkr306.09 Million NOK (≈ $32.21 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr656.62 Million ≈ $69.10 Million USD) and total liabilities (Nkr350.53 Million ≈ $36.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NAVA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr306.09 Million |
| % of Total Assets | 46.62% |
| Annual Growth Rate | 19.05% |
| 5-Year Change | 120.9% |
| 10-Year Change | 215.97% |
| Growth Volatility | 48.07 |
Net Assets of Navamedic ASA (2003–2025)
Net assets of Navamedic ASA from 2003 to 2025. This chart illustrates how Navamedic ASA's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Navamedic ASA to measure how much of total assets are equity-financed.
Annual Net Assets for Navamedic ASA (2003–2025)
The table below shows the annual net assets of Navamedic ASA from 2003 to 2025. For live market cap and overall valuation, see how much is Navamedic ASA worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr334.08 Million ≈ $35.15 Million |
+38.95% |
| 2024-12-31 | Nkr240.44 Million ≈ $25.30 Million |
+8.11% |
| 2023-12-31 | Nkr222.39 Million ≈ $23.40 Million |
+6.04% |
| 2022-12-31 | Nkr209.72 Million ≈ $22.07 Million |
+38.67% |
| 2021-12-31 | Nkr151.24 Million ≈ $15.91 Million |
+16.80% |
| 2020-12-31 | Nkr129.49 Million ≈ $13.63 Million |
+63.43% |
| 2019-12-31 | Nkr79.23 Million ≈ $8.34 Million |
-20.23% |
| 2018-12-31 | Nkr99.32 Million ≈ $10.45 Million |
+2.71% |
| 2017-12-31 | Nkr96.70 Million ≈ $10.18 Million |
-8.54% |
| 2016-12-31 | Nkr105.73 Million ≈ $11.13 Million |
-10.61% |
| 2015-12-31 | Nkr118.28 Million ≈ $12.45 Million |
+6.34% |
| 2014-12-31 | Nkr111.23 Million ≈ $11.70 Million |
+3.71% |
| 2013-12-31 | Nkr107.26 Million ≈ $11.29 Million |
+10.95% |
| 2012-12-31 | Nkr96.68 Million ≈ $10.17 Million |
+3.69% |
| 2011-12-31 | Nkr93.24 Million ≈ $9.81 Million |
-6.95% |
| 2010-12-31 | Nkr100.21 Million ≈ $10.54 Million |
-10.36% |
| 2009-12-31 | Nkr111.78 Million ≈ $11.76 Million |
+1.40% |
| 2008-12-31 | Nkr110.24 Million ≈ $11.60 Million |
-14.54% |
| 2007-12-31 | Nkr128.99 Million ≈ $13.57 Million |
+111.93% |
| 2006-12-31 | Nkr60.87 Million ≈ $6.40 Million |
+40.93% |
| 2005-12-31 | Nkr43.19 Million ≈ $4.54 Million |
+126.94% |
| 2004-12-31 | Nkr19.03 Million ≈ $2.00 Million |
+163.94% |
| 2003-12-31 | Nkr7.21 Million ≈ $758.70K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Navamedic ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Navamedic ASA Net Assets Breakdown (December 2025)
Navamedic ASA net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Nkr1.88 Million | 0.56% |
| Common Stock | Nkr17.75 Million | 5.31% |
| Other Components | Nkr314.45 Million | 94.13% |
| Total Equity | Nkr334.08 Million | 100.00% |
Navamedic ASA Competitors by Market Cap
The table below lists competitors of Navamedic ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Epitomee Medical Ltd
TA:EPIT
|
$28.14 Million |
|
Pasdec Holdings Bhd
KLSE:6912
|
$28.15 Million |
|
TPC Mechatronics Corporation
KQ:048770
|
$28.15 Million |
|
Profoto Holding AB
ST:PRFO
|
$28.15 Million |
|
Beyaz Filo Oto Kiralama AS
IS:BEYAZ
|
$28.13 Million |
|
MicroAlgo Inc.
NASDAQ:MLGO
|
$28.12 Million |
|
ML System S.A.
WAR:MLS
|
$28.11 Million |
|
Apollo Power Ltd
TA:APLP
|
$28.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Navamedic ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 240,437,000 to 334,077,000, a change of 93,640,000 (38.9%).
- Net loss of 23,538,000 reduced equity.
- Share repurchases of 130,202,000 reduced equity.
- New share issuances of 130,202,000 increased equity.
- Other comprehensive income decreased equity by 1,000.
- Other factors increased equity by 117,179,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-23.54 Million | -7.05% |
| Share Repurchases | Nkr130.20 Million | -38.97% |
| Share Issuances | Nkr130.20 Million | +38.97% |
| Other Comprehensive Income | Nkr-1.00K | -0.0% |
| Other Changes | Nkr117.18 Million | +35.08% |
| Total Change | Nkr- | 38.95% |
Book Value vs Market Value Analysis
This analysis compares Navamedic ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 6.91x to 0.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | Nkr1.61 | Nkr11.15 | x |
| 2004-12-31 | Nkr4.26 | Nkr11.15 | x |
| 2005-12-31 | Nkr9.67 | Nkr11.15 | x |
| 2006-12-31 | Nkr10.70 | Nkr11.15 | x |
| 2007-12-31 | Nkr20.33 | Nkr11.15 | x |
| 2008-12-31 | Nkr14.60 | Nkr11.15 | x |
| 2009-12-31 | Nkr14.61 | Nkr11.15 | x |
| 2010-12-31 | Nkr13.27 | Nkr11.15 | x |
| 2011-12-31 | Nkr11.88 | Nkr11.15 | x |
| 2012-12-31 | Nkr11.54 | Nkr11.15 | x |
| 2013-12-31 | Nkr12.47 | Nkr11.15 | x |
| 2014-12-31 | Nkr12.98 | Nkr11.15 | x |
| 2015-12-31 | Nkr13.45 | Nkr11.15 | x |
| 2016-12-31 | Nkr10.27 | Nkr11.15 | x |
| 2017-12-31 | Nkr8.88 | Nkr11.15 | x |
| 2018-12-31 | Nkr9.13 | Nkr11.15 | x |
| 2019-12-31 | Nkr6.76 | Nkr11.15 | x |
| 2020-12-31 | Nkr8.95 | Nkr11.15 | x |
| 2021-12-31 | Nkr1.89 | Nkr11.15 | x |
| 2022-12-31 | Nkr12.32 | Nkr11.15 | x |
| 2023-12-31 | Nkr12.63 | Nkr11.15 | x |
| 2024-12-31 | Nkr13.61 | Nkr11.15 | x |
| 2025-12-31 | Nkr13.93 | Nkr11.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Navamedic ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.16%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 2.22x
- Recent ROE (-7.05%) is below the historical average (-2.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 6.72% | 556.84% | 0.11x | 0.11x | Nkr-236.55K |
| 2004 | 27.76% | 451.51% | 0.07x | 0.90x | Nkr3.38 Million |
| 2005 | -11.27% | -109.81% | 0.09x | 1.11x | Nkr-9.19 Million |
| 2006 | -12.44% | -1959.38% | 0.01x | 0.86x | Nkr-13.66 Million |
| 2007 | -2.49% | -10.09% | 0.17x | 1.44x | Nkr-16.11 Million |
| 2008 | -7.33% | -17.52% | 0.29x | 1.45x | Nkr-19.10 Million |
| 2009 | 11.46% | 24.37% | 0.39x | 1.22x | Nkr1.64 Million |
| 2010 | -11.16% | -20.31% | 0.45x | 1.23x | Nkr-21.21 Million |
| 2011 | -7.68% | -10.04% | 0.51x | 1.49x | Nkr-16.48 Million |
| 2012 | -3.37% | -3.67% | 0.66x | 1.38x | Nkr-12.92 Million |
| 2013 | -1.18% | -0.84% | 0.85x | 1.67x | Nkr-11.99 Million |
| 2014 | 1.17% | 0.59% | 1.05x | 1.92x | Nkr-9.82 Million |
| 2015 | -9.24% | -4.40% | 0.90x | 2.33x | Nkr-22.76 Million |
| 2016 | -10.08% | -3.89% | 0.95x | 2.72x | Nkr-21.23 Million |
| 2017 | -16.07% | -6.03% | 1.04x | 2.56x | Nkr-25.21 Million |
| 2018 | 7.33% | 3.96% | 0.86x | 2.16x | Nkr-2.65 Million |
| 2019 | -20.57% | -8.63% | 1.01x | 2.36x | Nkr-24.22 Million |
| 2020 | -12.71% | -7.84% | 0.81x | 2.01x | Nkr-29.41 Million |
| 2021 | 0.41% | 0.22% | 0.84x | 2.18x | Nkr-14.51 Million |
| 2022 | 14.03% | 7.70% | 1.00x | 1.83x | Nkr8.46 Million |
| 2023 | 1.49% | 0.65% | 0.98x | 2.36x | Nkr-18.94 Million |
| 2024 | 0.54% | 0.24% | 1.08x | 2.04x | Nkr-22.75 Million |
| 2025 | -7.05% | -4.16% | 0.76x | 2.22x | Nkr-56.95 Million |
Industry Comparison
This section compares Navamedic ASA's net assets metrics with peer companies in the Medical Distribution industry.
No peer company data available for comparison.
About Navamedic ASA
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition… Read more